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RESUMO 
A tuberculose humana é ainda uma das doenças infecciosas de maior incidência 
mundial, com 8.7 milhões de novos casos reportados em 2011. O aumento da taxa de 
infecções por tuberculose multi-resistente tem também imposto sérios riscos à saúde pública, 
especialmente em países em desenvolvimento. Resistência à isoniazida e rifampicina, dois 
antibióticos de primeira linha, está geralmente associada a mutações pontuais nos genes katG, 
inhA e rpoB de Mycobacterium tuberculosis complex (MTBC). O desenvolvimento de um 
método molecular barato, rápido e simples, capazes de aferir os perfis de susceptibilidade 
antimicrobiana, terá um grande impacto na capacidade de diagnóstico precoce e tratamento de 
doentes com tuberculose multi-resistente. 
Nanopartículas de ouro funcionalizadas com oligonucleotidos tiolados (nanossondas) 
têm mostrado o seu potencial de detecção rápida e sensível de MTBC, bem como de mutações 
associadas a resistência a antibióticos. Nomeadamente a caracterização dos três codões mais 
relevantes do gene rpoB, associados à resistência à rifampicina. Neste trabalho alargou-se a 
discriminação de mutações ao gene inhA associadas a resistência à isoniazida. Utilizando uma 
abordagem de multiplex PCR foi ainda possível amplificar os genes rpoB e inhA e aferir ambos 
os loci em paralelo, estendendo o potencial das nanossondas para a caracterização de 
tuberculose multi-resistente, com especial aplicação nos genótipos mais frequentes na região 
da Grande Lisboa.  
 
Palavras-chave: nanodiagnóstico; nanopartículas de ouro; tuberculose; multiplex PCR. 
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ABSTRACT 
Tuberculosis is still one of the leading human infectious diseases, with 8.7 million new 
cases reported in 2011 alone. Also, the increasing rate of multidrug-resistant tuberculosis 
(MDR-TB) and its treatment difficulties pose a serious public health threat especially in 
developing countries. Resistance to isoniazid and rifampicin, first line antibiotics, is commonly 
associated with point mutations in katG, inhA and rpoB genes of Mycobacterium tuberculosis 
complex (MTBC). Therefore, the development of a cheap, fast and simple molecular method to 
assess susceptibility profiles would have a huge impact in the capacity of early diagnosis and 
treatment of MDR-TB patients. 
Gold nanoparticles functionalised with thiol-modified oligonucleotides (Au-nanoprobes) 
have shown the potential to provide a rapid and sensitive detection method for MTBC and 
single base mutations associated with antibiotic resistance, namely the characterisation of the 
three most relevant codons in rpoB gene associated to rifampicin resistance. In this work the 
Au-nanoprobe approach is extended towards the discrimination of specific mutations within inhA 
gene which is associated with resistance to isoniazid. Using a multiplex PCR reaction for rpoB 
and inhA genes, it was possible to assess both loci in parallel, and extend the potential of the 
Au-nanoprobe method to MDR-TB molecular characterisation with special application in the 
most frequent genotypes circulating in the Lisbon Health Region. 
 
Keywords: nanodiagnostics; gold nanoparticles; tuberculosis; multiplex PCR.  
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1. INTRODUCTION 
1.1 Tuberculosis 
Fighting Tuberculosis (TB) remains one of the biggest challenges of our times. Killing 1.4 million 
people in 2011 it is the second worldwide killer especially in developing countries, which account for 
95% of the deaths. Despite largely curable when accurately diagnosed and treated, one third of the 
8.7 million estimated new cases in 2011 were undiagnosed or unreported leading to continuous 
spread of the disease. Insufficient access to diagnostic tests sets one of the biggest barriers for TB 
control (WHO, 2012). 
In spite of the dropping mortality numbers that account for a reduction of 41% since 1990, cases 
of multidrug resistant tuberculosis (MDR-TB) – resistance to two first line antibiotics – are increasing. 
Such cases impose serious risks for public health, which could be avoided with an accurate and early 
diagnosis, improving treatment effectiveness. However, the percentage of undiagnosed or unreported 
cases for MDR-TB is 81% worldwide, also demonstrating the need for new diagnostic tools to assess 
resistance profiles (WHO, 2012).  
 
1.1.1 Mycobacterium tuberculosis 
The most common mode of TB infection is by inhalation of aerosols containing viable 
microorganisms. Mycobacterium tuberculosis is the main etiological agent of TB in humans and part of 
the Mycobacterium tuberculosis complex (MTBC) that includes other human infecting subspecies. 
Described as fairly large, non-motile, rod-shaped bacterium distantly related to the Actinomycetes, its 
cellular wall is rich in mycolic acids impermeable to common dyes and stains used in bacterial studies. 
Acid-fast staining, such as Ziehl-Neelsen, is therefore the most commonly used for its microscopy 
visualisation. Mycobacterium tuberculosis is an obligate aerobe, facultative intracellular parasite 
usually found in lung alveoli. Able to evade standard immune system digestion mechanisms, it 
survives and replicates inside macrophages with a generation time of 15 to 20 hours, which makes 
them hard to grow in culture (McMurray, 1996).  
TB is an infectious disease of mandatory notice, divided into two types, active and latent. The 
active type is characterised by coughing, weight loss, fever, night sweats and in some cases coughing 
blood; other forms of extrapulmonary tuberculosis are described, but are rare and restricted to 
immunodepressed patients. The latent TB is asymptomatic, not contagious, and accounts for 95% of 
infected cases. Patients can remain infected for years without being diagnosed, of which 10% will 
evolve to an active form of the disease (McMurray, 1996; WHO, 2012). 
 
2 
 
1.1.2 TB Treatment 
TB treatments consist on long regimens of multiple antibiotics. For new patients, where no 
resistance is suspected, the treatment consists of 2 months of 4 first-line antibiotics (isoniazid, 
rifampicin, pyrazinamide, and either ethambutol or streptomycin) followed by 4 months of rifampicin 
(RIF) and isoniazid (INH). If resistances are found, second-line antibiotics are administered for up to 
24 months. Directly observed therapy is recommended for all patients since they tend to stop or 
reduce the medication when they recover during the first weeks of treatment, increasing the risk for 
resistances. Ideally all diagnosed patients should stay in isolation until negative sputum smear – 
usually after approximately 2-4 weeks of treatment when they are considered not contagious – 
however this is not a reality in TB high-burden countries (ATS et al., 2003). 
 
1.1.3 Mechanisms of Resistance 
Unlike other bacteria, which drug resistance is generally acquired through horizontal transfer 
by mobile genetic elements, M. tuberculosis acquires drug resistance mainly by spontaneous 
mutations in chromosomal genes, due to selection of resistant strains during sub-lethal drug therapy 
(Silva and Palomino, 2011). Since the two most relevant antibiotics are RIF and INH, their 
mechanisms of resistance will be clarified.  
RIF is an antibiotic of the rifamycin group that acts by binding to the active site of RNA 
polymerase beta subunit thereby blocking transcription. Alterations in single nucleotides confer 
resistance to RIF, making it recurrent in monotherapy schemes. An 81 bp region of rpoB gene (codons 
507-533) accounts for about 95% of all single nucleotide alterations in examined clinical isolates, 
where more than 35 distinct variations have been described. Among these, H526D and S531L 
mutations account for two-thirds of RIF resistance and are absent in susceptible isolates (Telenti et al., 
1993; Miller et al., 1994; Musser, 1995). These single mutation events are associated with high levels 
of RIF resistance, increasing its occurrence and making it one of the main reasons for treatment 
failure and fatal clinical outcome (Mitchison and Nunn, 1986).  
Resistance to INH is far more complex and its full mechanism of action is still not understood. 
It has been proposed that for INH effectiveness, it requires activation by a catalase-peroxidase 
enzyme encoded by katG. During this activation, the enzyme generates a hypothetical isonicotinic acyl 
radical that inhibits NADH-dependent enoyl-ACP reductase (encoded by inhA) which plays a role in 
the synthesis of essential mycolic acids (Vilcheze and Jacobs, 2007). INH resistance works therefore, 
either by loss of KatG activity (decreasing INH activation) or by InhA over expression (compromising 
its inhibition by the isonicotinic acyl radical). Mutations in inhA and katG are present in 75-85% of the 
cases (Musser, 1995; Zhang et al., 1992). However, mutations in other genes have also been related 
with resistance to INH such as ahpC, ndh, embB, kasA, furA, showing the complexity of INH action 
(Banerjee et al., 2008). The most common point mutation in clinical isolates lies in codon 315 of katG, 
with a serine to threonine substitution. This substitution is responsible for about 50-90% of the 
isoniazid resistant mutants globally but not in Portugal, where there is a high prevalence of MDR-TB in 
the Lisbon Health Region (Machado et al., 2013). More than 90% of these resistant strains show no 
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mutation in katG, but only in the promoter region of inhA (C-15T) coupled with mutations in inhA gene 
locus. Furthermore, inhA mutations have also been described as conferring cross-resistance to 
ethionamide (ETH) (Viveiros et al., 2010; Machado et al., 2013). The rpoB S531L and inhA C-15T are 
then the most common mutations in the Lisbon Health Region, conferring resistance to RIF, INH and 
ETH.  
 
1.1.4 Diagnostics 
Diagnosis of TB can be difficult since it shares the same early symptoms with other diseases. 
For that matter, clinicians have a broad range of screening tests to confirm the diagnosis (Wallis et al., 
2010). Mantoux tuberculin skin test and Interferon-γ release assays test the immune response of a 
patient to specific antigens of M. tuberculosis. They are the primarily screening methods, however 
they present low specificity with false positive results in BCG vaccinated patients (Mazurek et al., 
2007). Once suspected of TB, chest X-Ray radiography is taken to seek for abnormalities and acid-
fast bacilli smear microscopy is analysed, which despite rapid, has low sensitivity even when coupled 
to light-emitting diode microscopy (Parsons et al., 2011). Microorganisms are also grown in 
laboratorial culture using Löwenstein–Jensen medium. Cultures can provide drug-susceptibility 
profiles, but due to the low growing rate of Mycobacterium tuberculosis results can take 2 to 6 weeks. 
Meanwhile clinicians use molecular tests to support the diagnosis and start treatment. Several 
molecular methods are available on the market, but they are either cumbersome, expensive or require 
specialised equipment and technicians, making them unsustainable in developing countries (Parsons 
et al., 2011). They generally depend on nucleic acids-amplification tests (NAAT) and two of them are 
endorsed by World Health Organization: line probe assays and automated detection. Both methods 
reduce time of diagnosis by hours, and automated systems even discards the need for specialised 
training, but the price of both technologies restricts their use to developed countries (Wallis et al., 
2010; WHO, 2012). 
 
Table 1.1 Most relevant methods of TB diagnostisis 
Diagnostic Method Description Main strengths Main weaknesses 
Immunoassays 
Tuberculin 
skin Test 
(Mantoux) 
Immunological skin 
response to tuberculin 
Extensive 
practical and 
published 
experience 
Low sensitivity with 
immune 
compromised; cross-
reaction with BCG 
vaccine 
Interferon-γ 
Detection of released 
Interferon-γ to identify 
active MTBC infection 
Highly specific; 
relatively fast 
Moderate training; 
consumables 
dependent; imperfect 
sensitivity 
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Radiography 
Chest 
radiography 
Detection of 
abnormalities in 
pulmonary 
radiographies 
Indications and 
use not 
restricted to TB 
Low specificity; low 
sensitivity; requires 
equipment and 
trained interpreter 
Smear 
microscopy 
Ziehl-
Neelsen and 
LED 
Detect TB bacteria by 
common or fluorescent 
microscopy 
Rapid; low 
consumables 
Low sensitivity 
Culture 
Solid culture 
Detect TB bacteria 
(manual or automated) 
and screen drug 
susceptibility 
Good sensitivity; 
low equipment 
Slow 
Liquid culture 
High sensitivity; 
faster than solid 
culture 
Slow; extensive 
training, 
infrastructure and 
consumables 
dependent 
NAAT 
Line probe 
assays 
Strip tests, detect 
MTBC and assess INH 
and RIF resistance 
Rapid 
Moderate training; 
expensive 
Automated 
Systems 
Automated processing, 
detect MTBC and 
assess RIF resistance 
Rapid; almost 
no training 
required 
Expensive; 
equipment and 
consumables 
dependent 
Au-
nanoprobes 
Colorimetric detection 
of TB, assess RIF and 
INH resistance 
Rapid; cheap; 
easy-read 
Moderate training 
Note: Adapted from (Dorman, 2010; WHO, 2009); BCG, Bacillus Calmette-Guérin; LED, Light-Emitting Diode 
 
1.1.5 Current Needs 
There are two front lines in the combat for TB: treatment and diagnostics. Without new 
effective drugs on the market for over 40 years, TB is characterised as a disease of developing 
countries, with reduced interests for pharmaceutical industries (Parsons et al., 2011; Wallis et al., 
2010).  
Diagnostic technologies for instance have seen new improvements in the latest years, 
especially molecular diagnostics. These molecular methods are based on NAAT, taking advantage of 
its high sensitivity and specificity, but require laboratories, trained personnel and are extremely 
expensive, which is the main bottleneck to overcome. 
The impact for the 22-high burden countries is estimated to be more than $3.4 trillion between 
2006 and 2015 if no anti-TB strategy is implemented (Laxminarayan et al., 2009). To solve the TB 
problem a fast, accurate, simple, and mostly low cost technology for diagnostics is needed (Wallis et 
al., 2010).  
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1.2 Nanotechnology 
Nanotechnology can be defined as understanding, controlling and manipulating materials at 
dimensions between 1 and 100 nanometers (Debnath et al., 2009). Nanomaterials have been used 
since ancient times, as evidenced by the presence of gold nanoparticles (AuNPs) in medieval 
cathedrals’ stained glass windows. Just recently however, the interest in nanomaterials bloomed due 
to their wide range of applications, especially in the biomedical field. Carbon nanotubes, quantum dots 
and noble metal nanoparticles are examples of such nanomaterials (Eustis and El-Sayed, 2006). 
AuNPs in particular have shown great potential for theranostics, due to their physical and optical 
properties. With a high surface-area-to-volume ratio, they are great vectors for delivery of molecular 
cargo. Also, their optical properties make them a better alternative to common fluorophores used in 
molecular diagnostic (Dreaden et al., 2012; Veigas et al., 2012). In the following sections, I will outline 
the most important characteristics of AuNPs along with their method of synthesis, functionalisation, 
and application. 
 
1.2.1 Gold Nanoparticles 
1.2.1.1 Synthesis 
Various techniques have been described for the synthesis and functionalisation of AuNPs, 
with different sizes, shapes and capping. Each of these has unique characteristics and is used for 
different purposes. I will focus on the properties of 14 nm diameter, spherical, citrate capped AuNPs. 
AuNPs synthesis is performed in liquid medium starting by dissolution of chloroauric acid 
(HAuCl4) in water. Then, sodium citrate reduces Au
3+
 ions to Au
0
 that start to precipitate in the form of 
sub-nanometre particle clusters. These nanoparticles grow in diameter until they get saturated of 
sodium citrate that acts also as a capping agent, protecting them from aggregation. Its concentration is 
thus crucial to set the final AuNPs size, where higher sodium citrate concentrations promote the 
formation of smaller nanoparticles. The higher surface area-to-volume ratio in smaller particles makes 
them need more citrate to get surface saturated. This method of synthesis produces relatively 
monodisperse nanoparticles that due to their size, are stable in water, forming an homogenous colloid 
that does not precipitate nor aggregate (Ji et al., 2007).  
 
1.2.1.2 Functionalisation 
Since citrate interactions with gold are weak (adsorption), functionalisation with biomolecules 
is generally easy through amine and thiol groups that interact strongly with gold (chemisorption) (Love 
et al., 2005). Several methods for nanoparticle functionalisation with DNA are described in the 
literature, but only functionalisation with 5’ thiol modified oligonucleotides by salt-aging and pH-
assisted methods will be addressed in this thesis (Zhang et al., 2012). The salt-aging method consists 
of the continuous addition of a salt solution that reduces repulsions between nanoparticles and 
oligonucleotides (both negatively charged), thus assisting in the Au-thiol interaction. Anionic 
6 
 
surfactants, such as sodium dodecyl sulfate (SDS) and ultrasounds are also used since they promote 
the general stabilisation of the system thus allowing higher salt concentrations that accelerate the 
functionalisation process. The pH-assisted method consists on lowering the AuNPs and DNA solution 
to pH 3 using sodium citrate. At pH 3 oligonucleotide and nanoparticle repulsion is reduced, 
accelerating functionalisation (Zhang et al., 2012). 
 
1.2.1.3 Physical and Optical Properties 
The most noteworthy physical property of AuNPs is their size, which affects their surface-area-
to-volume ratio and colloidal stability in solution (Eustis and El-Sayed, 2006). Uniformly surface 
charged, 14 nm diameter AuNPs are stable in water but start to precipitate at larger sizes (Alexander 
et al., 2013). An interesting effect is observed upon the addition of salt: momentary dipoles are 
generated at the nanoparticles’ surface, reducing the repulsion between them and promoting their 
irreversible aggregation. Aggregated nanoparticles behave as bigger nanoparticles despite not being 
chemically bonded. This occurrence affects their stability in solution, promoting precipitation, and their 
special optical properties (Sato et al., 2005). 
When matter interacts with light several phenomena can occur and light can be: absorbed, 
scattered (i.e. or Rayleigh scattering) or absorbed and re-emitted (i.e., fluorescence). In the case of 
AuNPs all these phenomena are strongly enhanced due to the unique interaction of light with free 
electrons on their surface. Since light wavelength and nanoparticles are at the same scale, when gold 
nanoparticles are exposed to light, its electromagnetic field causes a collective oscillation of the 
conduction-band electrons at the surface of the nanoparticles, forming instantaneous dipoles. These 
dipoles cancel the electromagnetic radiation of the same frequency, “pseudo-absorbing” light (Eustis 
and El-Sayed, 2006). The synchronised oscillation of the free electrons with the electromagnetic field 
is called surface plasmon resonance (SPR). The SPR of gold nanoparticles depends on their size and 
shape; for spherical, 14nm diameter nanoparticles, the resonance occurs in the visible spectrum 
region (520nm) giving them a brilliant red colour (Huang et al., 2007). Bigger nanoparticles tend to 
blue colours due to a shift in the SPR peak to 600 nm region. When close enough, AuNPs change 
their optical properties, behaving as single bigger particles and shifting the SPR band to longer 
wavelengths. For that reason when AuNPs aggregate their colour changes to blue (Baptista et al., 
2006; Sato et al., 2005). 
 
1.2.2 Non-cross-linking Method 
Several approaches of DNA detection using AuNPs functionalised with oligonucleotides (Au-
nanoprobes) have been described (Baptista et al., 2006; Sato et al., 2003). In this work, a non-cross-
linking method was used, based on the Watson-Crick base pair complementarity of DNA and salt-
induced aggregation of AuNPs (Baptista et al., 2006; Watson and Crick, 1953). Basically, a DNA 
sample is added to the Au-nanoprobes followed by a salt that promotes the nanoprobes’ aggregation. 
In the presence of complementary DNA, the latter hybridises with the probe, protecting Au-
nanoprobes from aggregation. If the target is non-complementary, the Au-nanoprobes remain 
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unprotected, thereby aggregating. The colorimetric change of disperse versus aggregated 
nanoparticles allows a simple visual analysis which can also be quantified in a spectrophotometer. 
Due to the specificity of DNA base paring, single base mismatched sequences can be discriminated, 
since they confer less protection to the Au-nanoprobes than full complementary sequences (Veigas et 
al., 2010). 
 
1.2.3 Tuberculosis Detection with Au-nanoprobes 
Au-nanoprobes have already proven their potential in the molecular diagnostic of TB, 
distinguishing not only MTBC from Non-MTBC (Baptista et al., 2006; Costa et al., 2010) but also 
mutations associated with antibiotic resistance. Veigas et al. (2010) described the use of Au-
nanoprobes for the characterisation of the three most relevant codons in rpoB gene associated to RIF 
resistance (Veigas et al., 2010). Since Au-nanoprobes present higher stability in the presence of full 
complementary targets a two-probe approach was addressed, with one probe harbouring a wild type 
(WT) sequence and the other a mutated (Mut) sequence. Considering that biological targets can only 
be WT or Mut, the redundancy of the two probes gives robustness to the result (Veigas et al., 2010). 
For its simplicity, speed and low-cost, this method has the capacity to fulfil clinical needs at point-of-
care (Baptista et al., 2008). 
 
 
Figure 1.1 Au-nanoprobes non-cross-link method for the diagnostics of TB 
1.3 Scope of the Thesis 
The molecular methods for diagnostic of TB are still unsuited for clinical needs, especially in 
the most affected countries where resources are limited (Parsons et al., 2011). The huge impact of 
point-of-care diagnostic makes it an important research topic with direct implication in peoples’ lives. 
A method has already been developed for the discrimination of the most common mutations 
associated with resistance to RIF using Au-nanoprobes, but there is no method for the analysis of 
mutations associated with resistance to INH, the second most important TB drug. The scope of this 
work is thus to develop a molecular method at point-of-care, able to assess the most common inhA 
mutation associated with resistance to INH, prevalent in Portuguese strains. It will also be addressed 
the possibility of complementing the developed protocol with the existing method of rpoB mutation 
discrimination. The use of a one-step amplification method for both loci results in a more complete 
profile of resistances and reduces time and costs. 
  
8 
 
2. MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Equipment 
Table 2.1 Equipment 
Equipment model Company 
UV-Vis Spectrophotometer UV Mini-1240 Shimadzu, Germany 
UV-Vis Spectrophotometer Nanodrop ND-1000 Nanodrop Technologies, USA 
Microplate reader Infinite M200 with Absorbance module Tecan, Switzerland 
Microfuge 1-14 Sartorius Sigma SIGMA, Germany 
Thermal Cycler DNA Engine Bio-Rad, USA 
Gel Doc XR+ Molecular Imager system Bio-Rad, USA 
Ultrasonic bath Elmasonic S10H Elma, Germany 
pH meter Basic 20 with combined glass electrode 5209 Crison, Spain 
Power supply electrophoresis Bio-Rad, USA 
DLS, SZ-100 Horiba, Japan 
 
2.1.2 Other Materials 
- Quartz Absorption Cell – 105.202-QS (Hellma, Germany) 
- NAP-5 columns (GE Healthcare, Sweden) 
- 384 well small volume, LoBase Polystyrene microplates, black (Greiner Bio-One, Germany) 
 
2.1.3 Chemical Reagents 
The chemicals used in this work were purchased from Sigma-Aldrich with the highest purity available 
unless stated otherwise. 
 
2.1.4 Biological reagents 
Table 2.2 Biological reagents 
Product Company 
dNTPs Mix Bioline, United Kingdom 
DreamTaq DNA polymerase Fermentas, Canada 
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GelRed® Fermentas, Canada 
GeneRuler™ DNA Ladder Mix, ready-to-use Fermentas, Canada 
Oligonucleotides StabVida, Portugal 
RNase A endoribonuclease Fermentas, Canada 
 
2.1.5 Biological Sequences 
All the following oligonucleotides 5’-thiol-(CH2)6 modified were resuspended in 100 μL of 1 M DTT and 
incubated for 1 h at room temperature. Afterwards, 900 μL of sterile milli-Q H2O was added to achieve 
a final concentration of 0.1M Dithiothreitol (DTT) and stored at -20ºC. 
All the following non-modified oligonucleotides were resuspended in sterile milli-Q H2O to achieve a 
final concentration of 100 pM and stored at -20ºC. 
 
Table 2.3 Biological Sequences 
Name Sequence (5’- 3’) 
Comment
s 
rpoB FW * GAG AAT TCG GTC GGC GAG CTG ATC C Primer 
rpoB RV * CGA AGC TTG ACC CGC GCG TAC ACC Primer 
inhA FW * CCT CGC TGC CCA GAA AGG GA Primer 
inhA RV * ATC CCC CGG TTT CCT CCG GT Primer 
inhA -15 WT 
Comp. 
AAT CAT CCC GTA ACA TAG TAG TCT CGC CGC GGC CGG GCC G Target 
inhA C-15T 
Comp. 
AAT CAT CCC GTA ACA TAG TAA TCT CGC CGC GGC CGG GCC G Target 
rpoB 531 WT 
Comp. 
AAT CAT CCC GTA ACA TAG CAC AAG CGC CGA CTG TCG GC Target 
rpoB S531L 
Comp. 
AAT CAT CCC GTA ACA TAG GAC AAG CGC CGA CTG TCG GC Target 
MTBC Comp. TGG AAC TAT GAG TTG GAC GTG GAG GCG ATC Target 
Non-Comp. TTG AGT ATC AAG GTG ATC GCC TCC ACG TCC Target 
MTBC * Thiol - GAT CGC CTC CAC GTC C Probe 
rpoB 531 WT * Thiol - GCC GAC AGT CGG CGC TTG TG Probe 
rpoB S531L * Thiol - GCC GAC AGT CGG CGC TTG TC Probe 
inhA -15 WT Thiol - CGG CCC GGC CGC GGC GAG AC Probe 
inhA C-15T Thiol - CGG CCC GGC CGC GGC GAG AT Probe 
* Note: The rpoB primers and probes, and the MTBC probe were defined according to Veigas et. al (2010). The 
inhA primers were designed in collaboration with Grupo de Micobactérias, at Instituto de Higiene e Medicina 
Tropical (IHMT/UNL), Portugal.  
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2.1.6 Solutions 
 AGE I 
2% (w/v) SDS 
10 mM phosphate buffer pH 8 
Sterilised by filtration (0.22 μm) and stored at 4ºC. Warm up to 25ºC before used. 
 
 AGE II 
1.5 M NaCl 
0.01% (w/v) SDS 
10 mM phosphate buffer pH 8 
Sterilised by filtration (0.22 μm) and stored at 4ºC. Warm up to 25ºC before used. 
 
 Alkaline Lysis I (ALI) 
50 mM Glucose 
25 mM Tris-HCl pH 8 
10mM EDTA pH 8 
Sterilised by autoclaving and stored at 4ºC. 
 
 Alkaline Lysis II (ALII) 
200 mM NaOH 
1% (w/v) SDS freshly prepared (room temperature). 
 
 Alkaline Lysis III (ALIII) 
3M sodium acetate (The pH was adjusted to 4.8 with glacial acetic acid) 
Stored at 4ºC and kept in ice during use. 
 
 Aqua Regia 
One volume of HNO3 to three volumes of HCl 
 
 Luria-Bertani (LB) medium  
1% (w/v) tryptone 
0.5% (w/v) yeast extract 
171 mM NaCl 
The pH was adjusted to 7 with NaOH, sterilised by autoclaving and stored at 4ºC. 
 
 Phosphate buffer (10 mM) pH 8.0 
9.32mM Na2HPO4 mM 
0.68 mM NaH2PO4 
Sterilised by autoclaving and stored at 4ºC. 
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 Sodium Citrate (0.5M) pH 3 
0.5M sodium citrate 
The pH was adjusted to 3 with pure HCl, sterilised by autoclaving and stored at 4ºC. 
 
 TAE Buffer 1X 
40 mM Tris-Acetate 
1 mM EDTA 
Tris-acetate was made with Tris-Base and Glacial Acetic Acid. The solution was sterilised by 
autoclaving and stored at 4ºC until further use. 
 
2.2 Methods 
2.2.1 Molecular Biology 
2.2.1.1 Plasmid Extraction 
1. An E. coli colony was inoculated in 10 mL of LB medium with 100 μg/mL ampicillin and 
incubated at 37ºC 16h with agitation. 
2. Cells were pelleted by centrifuging at 1844g for 5 min in 1.5 mL tubes. 
3. The supernatant was discarded and the pellet was resuspended in 100 μL of ice-cold AL I 
solution. 
4. After 5 minutes on ice, 200 μL of AL II solution was added and mixed by inversion. 
5. After 5 minutes on ice, 150 μL of AL III solution was added and mixed by vortex. 
6. After 15 minutes on ice, the lysate was centrifuged at 21,460 g for 5 minutes. 
7. The supernatant was transferred to a sterile tube and 2 volumes of ice-cold 100% ethanol 
were added. 
8. The plasmid DNA was left to precipitate at -20ºC for 2 hours 
9. The precipitate was centrifuged at 21460 g for 15 minutes and the supernatant was discarded. 
10. The pellet was washed with 500 μL of ice-cold 70% ethanol. 
11. The pellet was dried with the help of a speed-vac and resuspended in 50 μL of sterile milli-Q 
H2O. 
12. RNase A was added to a final concentration of 25 μg/ml and incubated for 1 hour at 37ºC. 
13. Two extractions with 1 volume of phenol were performed, followed by one extraction with 
chloroform. 
14. Plasmid DNA was precipitated with ethanol by repeating steps 7 to 11 
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2.2.1.2 Polymerase Chain Reaction 
Simplex reaction 
 
1x DreamTaq Buffer 
0.2 μM primer Fw 
0.2 μM primer Rv 
0.2 mM dNTP mixture 
0.1 U/μL DreamTaq polymerase 
 
 
Reaction program 
 
5 min 94º Pre-Denaturation 
30s 94º Denaturation 
30s 58º Annealing 
45s 72º Extension 
5min 72º Final Extension 
Pause 4º 
 
2.2.2 Nanotechnology 
2.2.2.1 Synthesis of Gold Nanoparticles adapted from Lee and Meisel (1982) 
All glass materials used for the synthesis of AuNPs were previously immersed in aqua regia for 2 
hours and later washed with milli-Q H2O (18.2 MΩ.cm at 25 °C). All metal materials used during 
synthesis were covered with Teflon and Milli-Q H2O was used in all solutions. 
1. In a 500 mL round bottom flask, 250 mL of 1 mM HAuCl4 were brought to a boil while in reflux 
and vigorously stirring. 
2. Then 25 mL of 38.8 mM sodium citrate were added and after 20 minutes the colloidal solution 
was left to cool to room temperature. 
3. The solution was then transferred to a 500 mL Erlenmeyer and stored in the dark at room 
temperature. 
4. AuNPs concentration was determined by the Lambert–Beer law assuming a molar absorptivity 
for the SPR peak (526 nm) of 2.33×10
8
 M
−1
 cm
−1
 (Baptista et al., 2005). 
5. Morphological characterisation of the AuNPs was performed by Transmission Electron 
Microscopy (TEM) and Dynamic Light Scattering (DLS). 
 
2.2.2.2 Thiol-modified Oligonucleotides Preparation 
1. One volume of thiol-modified oligonucleotide was extracted with two volumes of ethyl acetate. 
2. The organic phase was discarded after centrifuging for 5 minutes at 21460 g. 
3. Two more extractions were performed repeating steps 1 and 2. 
35 cycles 
Multiplex Reaction 
 
1x DreamTaq Buffer  
0.2 μM inhA Fw 
0.2 μM inhA Rv 
0.2 μM rpoB Fw 
0.2 μM rpoB Rv 
0.4 mM dNTP mixture 
0.1 U/μL DreamTaq polymerase 
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4. The remaining aqueous phase was further purified through a NAP-5 column, accordingly to 
manufacturer’s instructions, using 10 mM phosphate buffer pH 8 as eluent. 
5. The purified thiol-modified oligonucleotide was quantified by UV/Vis spectroscopy with help of 
NanoDrop, using the optical density at 260 nm provided. 
 
2.2.2.3 Synthesis of Nanoprobes (Salt-Aging Method) 
1. In a polypropylene 25 mL vial with a conical skirted base, the purified thiol-modified 
oligonucleotide was mixed with a ~15 nM AuNPs solution in a theoretical ratio of 1:200 (AuNP:oligos). 
2. AGE I solution was then added to achieve a final concentration of 10 mM phosphate buffer pH 
8, 0.01% (w/v) SDS. 
3. Afterwards, the ionic strength of the solution was sequentially increased in 50 mM increments 
by adding a certain volume of AGE II solution up to a final concentration of 10 mM phosphate buffer 
pH 8, 0.3 M NaCl, 0.01% (w/v) SDS and let rest at room temperature for an o/n period. 
NOTE: After each AGE solution addition, the vial was submersed in an ultrasound bath for 10 
seconds and let to rest at room temperature for 20 minutes before the next increment. 
4. The functionalised AuNPs were distributed in 2 mL tubes and centrifuged at 21460 g for 40 
minutes. 
5. The supernatant was discarded and the resulting oily pellet was washed twice with 10 mM 
phosphate buffer pH 8 and once with 10 mM phosphate buffer pH 8 0.1M NaCl. 
6. The resulting pallets were than mixed and the concentration of functionalised AuNPs was 
determined by the Lambert–Beer law assuming a calculated molar absorptivity for the SPR peak (526 
nm) of 2.33×10
8
 M
−1
 cm
−1
. 
7. By diluting the resulting functionalised AuNPs solution (stock solution) with 10mM phosphate 
buffer pH 8 0.1M NaCl a final concentration of 15 nM was obtained and the colloidal solution was 
stored in the dark at 4ºC. 
 
2.2.2.4 Synthesis of Nanoprobes (pH Assisted Method) 
1. In a polypropylene 25 mL vial with a conical skirted base, the purified thiol-modified 
oligonucleotide was mixed with a ~15 nM AuNPs solution in a theoretical ratio of 1:200 (AuNP:oligos). 
2. Then, 500mM sodium citrate pH 3 was added up to a final concentration of 20mM and let the 
solution rest for 30min. 
3. Steps 4-7 of Salt-Aging Method were performed 
 
2.2.2.5 Nanoprobes Stability Assays 
1. A solution containing 15 nM Au-nanoprobe (Au-nanoprobe final concentration of 2.5 nM) and 10 
mM phosphate buffer pH 8 alone was prepared by heating for 10 minutes at 95ºC and cool down for 
10 minutes at 24 ºC 
2. The solution was mixed with increasing concentrations of MgCl2 solution to fulfil a total volume of 
30 μL. 
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3. The solutions were transferred to microplate wells and UV-visible spectroscopic measurements 
were registered 30 minutes after salt addition in a microplate reader. 
 
2.2.2.6 Non-cross-linking Detection Assays 
1. Assay solutions containing the Au-nanoprobes and target DNA were prepared by mixing the 
appropriate DNA sample with the Au-nanoprobe solution (final concentration 2.5 nM), and by using 10 
mM phosphate buffer pH 8 to fulfil the final volume. A blank solution was prepared by replacing the 
DNA for an equivalent volume of 10 mM phosphate buffer pH 8. 
2. The solutions were heated for 10 min at 95ºC and then allowed to cool down for 10 minutes at 
24 ºC. 
3. The solutions were mixed with specific concentrations of MgCl2 solutions to fulfil a total 
volume of 30 μL (Au-nanoprobe final concentration of 2.5 nM). 
4. The solutions were transferred to microplate wells and UV-visible spectroscopic 
measurements were registered 30 minutes after salt addition in a microplate reader. 
 
2.2.2.7 TEM Analysis 
Samples of AuNPs were sent to Instituto de Ciência e Engenharia de Materiais e Superfícies 
(ICEMS/IST), Portugal, for TEM analysis. The samples were prepared by depositing 10 μL of the as-
prepared colloidal suspensions in carbon copper grids, washing twice with 10 μL of Milli-Q water, and 
air dried. TEM was performed with a HITACHI H-8100 microscope operated at 200 kV. Particles size 
and shape were determined by analysing the TEM pictures using the imaging software Carnoy 2.0. 
 
2.2.2.8 DLS Analysis 
The hydrodynamic diameter of AuNPs was determined by DLS. A total volume of 100 μL of 2.5 nM 
AuNPs was first stabilised for 15 minutes at 25ºC and then a total of 60 μL was measured for each 
sample. DLS analyses were performed at Departamento de Quimica (FCT\UNL). 
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3.  RESULTS AND DISCUSSION 
3.1 Design and Characterisation of inhA primers and probes  
3.1.1 Primers and Probe Design 
RIF resistance is mostly characterised by mutations in rpoB gene, with special relevance to 
codon 531. The nucleotide sequences used for amplification and detection of this gene were 
previously described in literature by Veigas et al. (2010). The rpoB PCR primers used are specific for 
MTBC members, and the MTBC probe serves as second line MTBC identification. Using this probe, 
electrophoretic gel analysis is discarded, since it serves as indicator of PCR amplification (Veigas et 
al., 2010). The probe used for mutation discrimination within the rpoB gene harboured the mismatch at 
the 3’ nucleotide as it is the best discriminating position (Doria et al., 2007; Veigas et al., 2010).  
INH resistance in Portugal is characterised by mutation in inhA, namely in its promoter region. 
inhA primers were designed considering that they should flank the mutation site and that their melting 
temperatures (TM) should be similar to the ones from rpoB primers, thus allowing the amplification of 
both loci in parallel. When designing inhA amplicon size it was taken in consideration that it should be 
different enough from rpoB to allow electrophoretic gel analysis differentiation during development 
stage, and close enough to have similar hybridisation kinetics – inhA amplicon size was 248 bp and 
rpoB, 395 bp. The chosen inhA primer sequences flanked the mutation site and had similar primer 
melting temperatures to the rpoB primers – inhA primers TM was 62º and 63.5º; and rpoB primers TM 
was 63º and 66º. The inhA probe was also designed to harbour the mismatch at the 3’ nucleotide. 
 
3.1.2 Target Preparation 
During the development stage of this work, DNA sequences of MTBC were required. In order 
to be independent from DNA extraction of limited biological samples, four plasmids were designed and 
cloned in collaboration with Faculdade Farmacia, UL, Portugal. These clones contained both WT and 
Mut sequences of inhA and rpoB genes.  
The first step of this thesis was to extract plasmid DNA from inhA -15 WT and inhA C-15T 
clones by alkaline lysis. The successful extraction was confirmed by electrophoretic analysis in 
agarose gel and by spectroscopy (Figure 3.1). Presence of a single absorbance peak at 260 nm 
indicated high purity of DNA without contaminants. A PCR reaction using inhA primers was optimised 
using different thermo cycler programs as well as different reagent concentrations. Both inhA WT and 
Mut PCR products were sequenced and mutation sites were confirmed (Figure 3.1 and Appendix A1). 
The PCR products were analysed by UV-Vis, the DNA concentration was calculated using Nanodrop 
ND-1000 (Nanodrop Technologies, USA) and the targets were used for Au-nanoprobes detection. 
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Figure 3.1 Electrophoretic analysis in 1% agarose gel of inhA WT and Mut plasmids (lane 2-3) and 
respective PCR products (lane 4-5) amplified with inhA primers (248 bp amplicon); lane 6 is the 
negative control 
3.1.3 AuNPs Synthesis and Characterisation 
Citrate capped AuNPs, were synthesised to achieve a final average diameter of 14nm, as 
previously described in similar non-cross link approaches (Costa et al., 2010; Veigas et al., 2010). 
After synthesis, three different techniques were used to confirm the desired size. Firstly the UV-Vis 
spectrum was analysed and theoretical size was calculated using equation 3.1 (Haiss et al., 2007). 
Presence of a single 520 nm SPR peak indicates relatively monodisperse spherical particles and the 
calculated mean diameter was 13.5 nm.  
𝑑 = 3
𝐴𝑏𝑠520
𝐴𝑏𝑠450
− 2.2 
 
Equation 3.1 Equation to calculate AuNPs’ mean size using UV-Vis spectrum; d is the mean diameter 
and Abs is the absorbance value at the described wavelength (Haiss et al., 2007). 
  
Characterisation through DLS can also give information about AuNPs size. This technique is 
based on the differential scattering of colloids according to their Brownian movement in solution, which 
is directly related to the AuNPs size or, more precisely its hydrodynamic radius. The hydrodynamic 
radius of AuNPs is for instance affected by the molecules at its surface, either capping or 
functionalisation (Kato et al., 2009). The DLS analysis revealed an AuNPs mean diameter size of 17.4 
nm (+ 0,415) which is higher than the previous calculated diameter (Figure 3.3). This can be explained 
by the citrate capping of the AuNPs that lead to an increase in its hydrodynamic radius. The DLS 
result for this reason converges with calculated UV-Vis spectrum size, indicating the expected AuNPs 
size.  
The third method used for the characterisation of AuNPs was TEM. This method allowed the 
direct visualisation of the AuNPs core and shape and the definite confirmation of their size. Ten 
random pictures were taken and nanoparticle size was measured representing a total of 387 counted 
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AuNPs. The expected size and shape were confirmed, with mean a diameter of 13.9 nm (+ 1.7 nm) 
spherical AuNPs (Figure 3.2).  
 
 
   
Figure 3.2 Characterisation of AuNPs by TEM; A) TEM picture of spherical nanoparticles with 
approximate 14 nm diameter size; B) histogram of analysed particles by measured diameter, with a 
mean diameter of 13.9 nm (+ 1.7 nm) 
 
3.1.4 Au-nanoprobes Characterisation 
After guaranteeing the desired size and shape of the AuNPs, functionalisation was performed 
using inhA -15 WT and inhA C-15T probe sequences with salt aging method. Three different 
approaches were used to confirm functionalisation. Firstly, both UV-Vis spectra were analysed and a 
shift in the SPR peak was observed from 520 nm to 525 nm, meaning an increase in the 
hydrodynamic radiuses. To prove this the probes were analysed by DLS, which confirmed an increase 
in diameter from 17.4 nm (+ 0,415) to 31 nm (+ 0,807) and 29.5 nm (+ 0,283) for WT and Mut probes 
respectively (Figure 3.3). Assuming that the distance between dsDNA base pairs is 0.34 nm (Watson 
and Crick, 1953) and knowing that the probe has 20 nucleotides, an increase of 13.6 nm in the 
hydrodynamic diameter would be expected (6.8 nm for each side). Considering also that the citrate 
capping is removed during functionalisation, 14 nm diameter gold core plus 13.6 nm of 
oligonucleotides should have approximately 27.6 nm. The difference between expected values and 
experimental values can be explained by: the thiol group size being ignored; Watson and Crick’s 
model referring to dsDNA while the probes are ssDNA; or by the solvation around AuNPs.  
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Figure 3.3 DLS Analysis of AuNPs and Au-nanoprobes; an increase in hydrodynamic radius is 
observed in both probes, when compared to naked particles from 17.4 nm (+ 0,415) to 31 nm (+ 
0,807) and 29.5 nm (+ 0,283). The quality of the data was assessed through the auto-correlation 
curves of the three measurements represented in Appendix A2 
 
The last evidence of functionalisation was the increase in AuNPs colloidal stability in solution. 
Citrate capped AuNPs easily aggregate in the presence of salts that increases the ionic strength in 
solution. After functionalisation, the oligonucleotides protect the AuNPs from aggregation maintaining 
their stability at higher salt concentrations (Sato et al., 2003). A series of stability assays were made 
and it was observed that the maximum shift in SPR peak was 570 nm, hence defining this wavelength 
as reference for AuNPs aggregated species. The 30 mM concentration of MgCl2 was defined as fully 
aggregating both probes, since the ratio between 525nm (SPR peak for dispersed particles) and 570 
nm was less than 1. This threshold was set to define whether there were more dispersed or 
aggregated nanoparticles in solution (Figure 3.4). 
 
 
Figure 3.4 Au-nanoprobes stability assays at various concentrations of MgCl2. The abs 525 nm / 570 
nm ratio was calculated and for values lower than 1 the nanoprobes were considerate full aggregated. 
For both WT and Mut probes 30 mM of MgCl2 was set as the concentration for full aggregation. 
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3.1.5 Au-nanoprobes Calibration 
Once proven the functionalisation of the AuNPs it was necessary to demonstrate their capacity 
to detect complementary targets and to discriminate single base mismatches. Synthetic 
oligonucleotides were firstly used since they are single stranded and have a high level of purity with 
much less interferents than PCR products. It was observed an increase in AuNPs stability upon 
hybridisation with a complementary target. This stabilisation effect is due to the steric hindrance 
created around AuNPs, since the synthetic oligonucleotides have not only a complementary region but 
also a ~20 bp tail. The formation of dsDNA structures, more rigid than ssDNA (Li and Rothberg, 2004) 
with oligonucleotide tails shields the AuNPs, reducing the probability of aggregation and increasing 
their stability.  
As the main scope of the thesis was to discriminate single base mismatches (point mutations 
related to drug resistance), the AuNPs’ efficiency toward discrimination of mismatched targets was 
also tested. The stated hypothesis was that mismatched targets would not stabilise AuNPs as much 
as full complementary targets. This proved to be correct with more Au-nanoprobes aggregated in the 
presence of mismatch targets than full complementary targets. This can be explained due to higher 
dissociation constants of mismatch targets conferring less protection to Au-nanoprobes in high ionic 
strength (Doria et al., 2007). The next step was to demonstrate the capacity of Au-nanoprobes to 
discriminate mutations using PCR products. 
 
 
Figure 3.5 Au-nanoprobes detection assays using 30 µg/mL of PCR product; 30mM of MgCl2 was 
used in all assays except from Probe; in Blank and Probe assays, no DNA was added. Higher 
stabilisation is observed in probes in presence of full complementary targets than single base 
mismatched. 
 
Several components of PCR interfere with Au-nanoprobes stability, such as salts, dNTPs and 
proteins (Eichmann and Bevan, 2010; Zhao et al., 2007). In order to remove these interferents the 
same volume of PCR product was added to each assay. Three replicate assays were performed for 
each probe. This way, the only variability between assays that had the same PCR product was the 
0.9
0.95
1
1.05
1.1
1.15
1.2
1.25
1.3
1.35
1.4
Probe Blank  inhA -15 WT inhA C-15T Non-Comp.
A
b
s
5
2
5
 /
 A
b
s
5
7
0
 
Target 
Detection assays 
inhA -15 WT Probe
inhA C-15T Probe
21 
 
probe used. The Au-nanoprobes then proved to be capable of discriminating single mutation in PCR 
products (Figure 3.5). Several concentrations of both targets were plotted using both probes in order 
to determine the best concentration for mismatch discrimination (Figure 3.6). The results showed a 
direct correlation between target concentration and Au-nanoprobes stability, where higher 
concentrations resulted in higher stability. This effect was more prominent when the probe and the 
target were fully complementary compared with mismatch cases. This can be explained by the 
different dissociation constants of DNA between full hybridised complementary sequences and 
mismatched ones. The range between ~20 µg/mL and ~50 µg/mL of target DNA set the lower and 
upper thresholds of DNA discriminative concentration. As 30 µg/mL presented the highest 
discriminating capacity for both probes, was used in the following assays.  
 
 
Figure 3.6 Optimisation of PCR product concentration for Au-nanoprobes discrimination assay. 
Various concentrations of A) inhA -15 WT target and B) inhA C-15T target were tested with inhA probe 
set. All assays were performed with 30 mM of MgCl2. The ratio between absorbance at 525 nm and 
570 nm was calculated and a range between ~20 µg/mL and ~50 µg/mL allowed discrimination 
between WT and Mut targets; 30µg/mL was defined as the best discriminative concentration 
3.2 Dual Loci Characterisation 
3.2.1 Au-nanoprobes Synthesis Method 
The salt aging method is long known and established, for functionalisation of AuNPs. 
However, functionalisation takes two days due to an overnight incubation during the process. Zhang et 
al. (2012) recently described a pH-assisted method for the functionalisation of AuNPs that takes just 
one day with the same results (Zhang et al., 2012). I tested this new method against the standard 
method to assess its applicability. Four MTBC probes were synthesised using the pH assisted 
synthesis protocol, with four theoretical ratios of AuNP:oligos – 1:50, 1:100, 1:150 and 1:200. During 
synthesis the 1:50 ratio probe aggregated and was therefore discarded from further tests. The other 
three probes were characterised and it was observed an increase in stability for higher 
functionalisation ratios, proving a growing density of oligos per nanoparticle (Figure 3.7). 
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Figure 3.7 Au-nanoprobes stability assays for pH-assisted synthesis; the following concentrations of 
MgCl2 were defined as the minimum to aggregate: Control, 20mM; Ratio 1:200, 17mM; Ratio:1:150, 
12mM; Ratio 1:100 10mM  
 
 Synthetic oligos and rpoB PCR products were then used for detection assays. A MTBC probe 
used as control was synthesised using the salt-aging method for method comparison. The results 
suggest a slightly higher stability when using a 1:200 ratio to discriminate between MTBC and non-
MTBC, however there was no statistically significant difference between any of the three studied ratios 
and the control (Figure 3.8). Curiously, the stability also increased with non-complementary targets 
along with the decrease in ratio functionalisation. This can be explained by unspecific DNA adsorption 
to Au-nanoprobes since they are less functionalised, that stabilises the nanoparticles.  
As no significant advantage was observed in using this new method of synthesis, all further 
assays were performed with salt-ageing synthesised probes. 
 
 
Figure 3.8 Au-nanoprobe detection assays using MTBC probe synthesised by pH assisted method 
with different ratios; the control probe was synthesised by salt-aging method; a complementary 
(MTBC) and a non-complementary target were used; for each probe the minimum salt concentration 
for aggregation was assayed and used (Figure 3.7). No statically significant difference was observed 
between probes 
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3.2.2 Multiplex PCR 
In order to simplify the method of DNA amplification and to reduce time and costs, a multiplex 
PCR approach was tested. The aim was to amplify the two most relevant loci associated with RIF and 
INH resistance in a single reaction, and test the capacity to discriminate both mutations in parallel. All 
the previous work of production and characterisation of targets and probes was repeated using MTBC, 
rpoB WT and rpoB Mut sequences. AuNPs were functionalised, characterised and tested to guarantee 
accurate discrimination.  
Multiplex PCR reactions were performed with both pairs of primers and twice the 
concentration of dNTPs. To prove it was possible to assess both loci, four reactions were prepared 
with the four possible combinations between WT and Mut templates of inhA and rpoB plasmids. 
Amplification of both templates was confirmed by agarose gel electrophoresis and similar intensities in 
both codons were observed (Figure 3.9). This demonstrates that the primers were accurately 
designed to have similar yields, since the same concentration of both templates was used, and the 
same amount of product was achieved.  
 
 
 
 
Figure 3.9 Electrophoretic analysis in 1% agarose of the four combinations of rpoB and inhA multiplex 
PCR products (lane 3-6) and simplex products (lane 7-8 for rpoB and lane 9-10 for inhA); lane 1 is the 
negative control 
 
3.2.3 Target Concentration for Detection Assays 
The optimal concentration of PCR amplified target for discrimination between WT and Mut 
sequences of rpoB locus was described in the literature as 30 µg/mL (Veigas et al., 2010); this 
concentration also proved to be the best for inhA locus. Since both amplicons showed similar 
amplification yields, a 60 µg/mL of multiplex PCR products was used in the detection assays.  
The four multiplex PCR products above mentioned were tested with both inhA and rpoB probe 
sets to confirm its ability to detect the desired mutations in parallel. In all cases the mutations were 
correctly assessed, with probes stabilising more in the presence of full complementary targets 
 1        2        3        4        5        6         7        8        9       10 
500 bp 
250 bp 
 
rpoB 531     ‒     WT    WT     Mut    Mut    WT     Mut      –        – 
inhA -15      ‒     WT    Mut     Wt    Mut     –         –       WT   Mut 
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compared to single base mismatched ones (Figure 3.10). However it was noted an overall decrease in 
stability, which can be explained by the volume of PCR product used in the assays. As twice the target 
concentration was needed, in general twice the volume of PCR product was added to each detection 
assay, resulting in twice the concentration of salts. Since no adjustment to the 30mM MgCl2 was done, 
multiplex PCR detection assays had more salts than simplex assays, leading to a general 
destabilisation of Au-nanoprobes (compare Figure 3.5 with Figure 3.10). 
 
 A)            B) 
  
Figure 3.10 Au-nanoprobe detection assays of multiplex PCR products. The four 
combinations of WT and Mut sequences of inhA -15 and rpoB 531 were tested with A) rpoB 531 probe 
set and B) inhA -15 probe set. The absorbance ratio 525 nm / 570 nm is used to assess the level of 
aggregation. For all combinations the correct genotype was assessed. 
 
Through electrophoretic analysis in agarose gel, it was noted in some cases a difference in 
amplification yield of both amplicons, which can be explained by the stochastic characteristics of PCR 
and/or by different plasmid template DNA in the reaction (Figure 3.11 A). For such cases Au-
nanoprobe detection was performed and despite the lower concentration of one of the amplicons it 
was still possible to accurately assess mutations (Figure 3.11 B, C). The reason for this is, as show in 
Figure 3.6, that mutation detection is possible when using between ~20 µg/mL and ~50 µg/mL of 
target DNA. Therefore, an accurate result can be obtained even in these cases despite the variability 
in PCR amplifications..  
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  A) 
 
 
 
 
B)        C) 
 
Figure 3.11 Au-nanoprobe detection using unbalanced multiplex PCR products. A) 
electrophoretic analysis in 1% agarose gel of four unbalanced products, two with higher amplification 
of inhA amplicon (lane 2-3) and two with higher amplification of rpoB amplicon (lane 4-5), lane 1 and 6 
are molecular rulers; B) Au-nanoprobe detection assays using the products from lanes 2-5 
respectively, with rpoB 531 probeset and C) inhA -15 probeset 
 
It was already proven that non-complementary PCR products do not interfere with the 
hybridisation of fully complementary targets in the Au-nanoprobes assays (Veigas, 2009). In this work 
it was shown that the capacity to detect single base mismatches is also unaffected by a non-
complementary target since a second amplicon did not interfere with the results accuracy. The 
capacity of Au-nanoprobes to detect single mutations is also unaffected by unbalanced multiplex 
amplifications, as long as the minimum discriminative concentration is present in the assays. 
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3.2.4 Data Analysis 
Aggregation profiles were analysed in terms of the ratio of Abs 525 nm / Abs 570 nm 
(dispersed vs. aggregated species) for each Au-nanoprobe. A threshold of 1 can be considered where 
values > 1 indicate that the Au-nanoprobes are mostly non-aggregated, whereas a value < 1 indicates 
aggregation. For the MTBC Au-nanoprobe, this approach indicates the presence or absence of MTBC 
DNA in the sample, serving as MTBC identifier and amplification sensor. In contrast, when using a set 
of Au-nanoprobes targeting WT and Mut sequences, the result is given by two probes, one fully 
complementary with the WT sequence and another with the Mut sequence. The most stable probe, 
which has a higher ratio of Abs 525 nm / Abs 570 nm in the presence of the target, sets the result. To 
assess two loci, it is necessary to analyse four values compared in pairs, so a simpler approach was 
used to ease results readout: the ratio between the Abs 525 nm / Abs570 nm value for the WT probe 
was divided by the ratio of the Mut probe (Equation 3.2).  
 
X =
WT 
Abs525
Abs570
Mut 
Abs525
Abs570
 
Equation 3.2 Ratio of WT \ Mut Au-nanoprobes. The absorbance ratio (525 nm / 570 nm) of WT 
probe is divided by the absorbance ratio of the Mut probe. When X > 1 the WT probe is more stable 
and when X < 1 the Mut is more stable 
 
Values >1 identify assays in which the WT probe was more stable than Mut probe, and thus 
the sample presented the WT sequence; whereas values <1 indicate the presence of mutation. With 
this approach the previous four values readout is reduce to a two values readout with a threshold of 
one. To exemplify the easiness of the read, the data of Figure 3.9 B was analysed using this approach 
(Figure 3.12).  
 
 
 
Figure 3.12 Analysis of data using ratio of WT and Mut probes; A) and B) represent data from Figure 
3.11 B,C analysed using Equation 3.2; values higher than one are considerate WT (in white) and 
lower Mut (in black) 
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3.2.5 Detection and Characterisation of Samples 
A methodology was then designed for the assessment of MTBC members, inhA -15 and rpoB 
531 mutations, consisting on a multiplex PCR and testing the products with the MTBC Au-nanoprobe; 
if the result returns negative (blue), no further testing is required since it is probably not TB. The test 
only fails if nucleic acids amplification is under the limit of detection, or in atypical TB; if the result 
returns positive (red), the two loci are evaluated to search for possible resistances (Figure 3.13).  
 
 
Figure 3.13 Schematics of multiplex PCR and Au-nanoprobes colorimetric detection. The two most 
relevant loci are amplified and MTBC probe is tested, then two sets of probes assess for mutations. 
The solutions spectra are taken and the stable probe (red), is compared with the unstable probe (blue) 
to set the result. In this case the sample would be MTBC positive and WT for both loci  
 
To prove the capacity of the methodology in a laboratory set up, biological samples where 
used. Mycobacterium DNA was extracted from sputum samples in collaboration with Prof. Miguel 
Viveiros and Prof. Isabel Couto from Grupo de Micobactérias, at Instituto de Higiene e Medicina 
Tropical (IHMT/UNL), Portugal. Hence two known samples – a M. tuberculosis reference sample and 
a M. kansasii (non-MTBC) – were successfully amplified and tested with the MTBC probe. The M. 
kansasii sample returned negative and the M. tuberculosis returned positive, further being used as 
negative and positive controls (Figure 3.14 A). For the M.tuberculosis sample, inhA -15 and rpoB 531 
mutations were also evaluated; as expected the sample had a WT genotype for both loci that was 
confirmed by sequencing analysis (Figure 3.14 B). 
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A)          B) 
  
Figure 3.14 Au-nanoprobes detection of negative and positive controls; A) MTBC probe was tested 
with the multiplex PCR product of M.tuberculosis sample and M. kansasii sample; B) M.tuberculosis 
multiplex PCR product was tested using inhA -15 and rpoB 531 probesets, the ratio of WT \ Mut 
probes was calculated; positive results are in white and negative in black  
 
For the proof-of-concept, a set of 25 DNA samples with susceptible and resistant genotypes 
were blindly tested with this methodology. The Mycobacterium DNA was extracted from pre-cultured 
sputum; the samples were amplified by multiplex PCR and the results were all positive when tested 
with the MTBC probe. Interestingly the two samples with lowest values of detection (1 and 21) were 
the ones with faintest PCR amplification. This means that a greater volume of PCR product was added 
to the assays to reach a concentration of 30 µg/mL. Consequently the Au-nanoprobes got more 
unstable due to salts in PCR that were not taken into account (Figure 3.15). 
 
 
Figure 3.15 Multiplex PCR products tested with MTBC probe where PC is the positive control and NC 
the negative control. The threshold of 1 sets the result; positive values are in white and negative in 
black 
 
Then inhA and rpoB probesets were used to assess the two relevant mutations (Appendix A3). 
For the rpoB 531 mutation, 3 samples had ratios of WT / Mut close to one (1 + 0.005), meaning that 
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the stability values for WT probes were almost the same as Mut probes, leading to inconclusive results 
(samples 3, 15, 25). The rpoB S531L mutation was detected in 9 samples indicating a profile of RIF 
resistance and the remaining samples were considered susceptibility with a WT genotype (Figure 3.16 
A). For inhA -15 mutation, 4 ratios had values close to one, lacking a conclusive result (samples 9, 13, 
18, 24). The inhA C-15T mutation was detected in 8 samples indicating a profile of INH resistance and 
the remaining samples were considerate WT with INH susceptibility (Figure 3.16 B). It is noteworthy 
that this genotyping analysis gives only an indication of the phenotype and not a definitive profile of 
resistance. 
 
 
A) 
 
B) 
 
Figure 3.16 Au-nanoprobe assays of the 25 samples where the ratio of WT probe was divided by the 
Mut probe; A) probe set ratio of rpoB 531, were values >1 indicate a WT genotype (in black) and <1 a 
Mut genotype (in white); B) the same approach used for inhA -15 probe set. 
 
The samples were tested with a commercial line probe assay screening test and with a liquid 
medium culture system (performed at Grupo de Micobácterias, IHMT). Comparing the Au-nanoprobes 
system results with the line probe assay a 100% concordance was attained for the MTBC probe, rpoB 
and inhA probesets. Also the 7 inconclusive results from both loci turned out to be correctly assessed 
showing that the threshold for undefined results (1 + 0.005) was incorrectly set. Meaning that despite 
being near 1, all ratios WT / Mut were accurate. It should be mentioned, that the Au-nanoprobe 
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strategy described is capable of the same level of detection but with reduced time, and costs, thus 
speeding up diagnostics. Interestingly within 11 mutated samples, 9 had both mutations, 1 had only 
inhA C-15T and 1 had only rpoB S531L showing that these mutations are correlated and tend to 
appear simultaneously between these mutations in the tested population, as it was previously describe 
in literature (Viveiros, 2005). 
The liquid medium culture analysis assessed the profile resistance of RIF and INH of the 25 
samples. For RIF resistance all samples were in concordance with the assessed genotype, with 10 
RIF resistant strains and 15 susceptible. For INH resistance, 14 samples showed resistance including 
the 10 inhA C-15T samples, and representing an accuracy of 84%. The four INH resistant samples 
that showed no inhA C-15T were sequenced and two mutations in katG locus were found, G494A 
(sample 3) and S315T (samples 4 and 6). In sample 13, no known mutation was detected, possibly 
representing a strain with an unknown mechanism of resistance (Table 3.1). As it was early explained, 
rpoB mutations are straightly related with RIF resistance, most precisely codon 531, as this study also 
corroborates. Mutations in inhA usually represent half of the INH resistant cases but not in the Lisbon 
Region where there is a higher incidence of this mutation, as the studied population demonstrates. 
These results indicate, once again, that the chosen mutations are the most relevant for RIF and INH 
resistance in Lisbon Region. 
 
Table 3.1 Phenotypes and genotypes of the tested samples, using liquid medium culture, line probe 
assay and Au-nanoprobe assay methods  
Sample 
Culture Line Probe Au-nanoprobe Other 
Mutations RIF/INH rpoB/inhA rpoB/inhA 
1 R/R +/+ +/+ 
 
2 S/S -/- -/- 
 
3 S/R -/- -/- katG G494A 
4 R/R +/- +/- katG S315T 
5 R/R +/+ +/+ 
 
6 S/R -/- -/- katG S315T 
7 S/S -/- -/- 
 
8 S/S -/- -/- 
 
9 S/S -/- -/- 
 
10 R/R +/+ +/+ 
 
11 S/S -/- -/- 
 
12 R/R +/+ +/+ 
 
13 S/R -/- -/- Not found 
14 S/S -/- -/- 
 
15 S/S -/- -/- 
 
16 R/R +/+ +/+ 
 
17 R/R +/+ +/+ 
 
18 S/R -/+ -/+ 
 
19 S/S -/- -/- 
 
20 S/S -/- -/- 
 
21 S/S -/- -/- 
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22 S/S -/- -/- 
 
23 R/R +/+ +/+ 
 
24 R/R +/+ +/+ 
 
25 R/R +/+ +/+ 
 
Note: R – Resistant; S – Susceptible; (+) – Mut; (-) – WT  
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4. CONCLUSION 
In this study, the already described method for the characterisation of rpoB mutations was 
successfully ported to the inhA C-15T mutation, hence allowing the complete characterisation of a new 
set of probes. The minimum salt concentration that induced both probes aggregation was defined at 
30 mM of MgCl2 as well as the best discriminating contraction between WT and Mut sequences using 
PCR product, 30 µg/mL. The advantages of using the pH assisted method for probe synthesis were 
not confirmed and consequently all probes were synthesised using the salt-aging method. It was also 
demonstrated a two-step approach based on the simultaneous PCR amplification of the two loci of 
interest followed by Au-nanoprobes characterisation of the molecular alterations involved in MDR-TB. 
These two mutations are particular to a specific geographic location with an uncommon and particular 
genotypic profile of MDR-TB, but clearly demonstrate the potential of the strategy for application to 
other clinical settings. A new method of data analysis was also proposed to simplify results read 
reducing the analysis of both codons from 4 values to 2 values. The Au-nanoprobe system proved to 
be capable of sensitive and specific detection of MTBC members and mutations associated with RIF 
and INH resistance, while being easy to perform without the need for expensive and complex 
laboratory set up. Following PCR amplification, the Au-nanoprobe system takes only 50 minutes to 
yield a colorimetric result that can be easily coupled to a portable device/platform that allows the 
analysis at a peripheral laboratory or in the field (Silva et al., 2011).  
However, this method does not solve all the problems, remaining some issues to overcome. 
Based on DNA genotyping it shares the same problems of all DNA molecular methods, namely: the 
characterisation of the genotype and not the phenotype, which are discordant in some cases; and not 
stating the cellular viability of the microorganisms. It still depends on nucleic acid amplification that 
requires lab technicians and routine lab material. Despite that, this technique proved to be as robust 
as others in the market, and bypassed a limiting factor, the cost, since the materials used have the 
potential to greatly lower the price of the final product, making it available at point-of-care.  
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APPENDIX 
A1 Results of the DNA sequencing analysis plus primers 
 
inhA amplification sequence 
 
CCTCGCTGCCCAGAAAGGGATCCGTCATGGTCGAAGTGTGCTGAGTCACACCGACAAACGTCAC
GAGCGTAACCCCAGTGCGAAAGTTCCCGCCGGAAATCGCAGCCACGTTACGCTCGTGGACATAC
CGATTTCGGCCCGGCCGCGGCGAGACGATAGGTTGTCGGGGTGACTGCCACAGCCACTGAAGG
GGCCAAACCCCCATTCGTATCCCGTTCAGTCCTGGTTACCGGAGGAAACCGGGGGAT 
 
rpoB amplification sequence 
 
CTGCGTACGGTCGGCGAGCTGATCCAAAACCAGATCCGGGTCGGCATGTCGCGGATGGAGCGG
GTGGTCCGGGAGCGGATGACCACCCAGGACGTGGAGGCGATCACACCGCAGACGTTGATCAAC
ATCCGGCCGGTGGTCGCCGCGATCAAGGAGTTCTTCGGCACCAGCCAGCTGAGCCAATTCATGG
ACCAGAACAACCCGCTGTCGGGGTTGACCCACAAGCGCCGACTGTCGGCGCTGGGGCCCGGCG
GTCTGTCACGTGAGCGTGCCGGGCTGGAGGTCCGCGACGTGCACCCGTCGCACTACGGCCGGA
TGTGCCCGATCGAAACCCCTGAGGGGCCCAACATCGGTCTGATCGGCTCGCTGTCGGTGTACGC
GCGGGTCAACCCGTT 
 
 
 
Figure A2 Autocorrelation curves of DLS measurements for inhA probes 
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Table A3 Ratio of WT probes (Abs525 \ Abs570) divided by ratio of Mut probes (Abs525 \ Abs570). 
Values >1 mean higher stability of WT probes, and <1 higher stability of Mut probes. Mutated 
genotypes (+) and wildtype (-). 
Sample 
Ratio rpoB WT/ 
rpoB Mut 
Ratio inhA WT/ 
inhA Mut 
rpoB 531 inhA -15 
1 0.907 0.979 + + 
2 1.052 1.023 - - 
3 1.005 1.079 - - 
4 0.978 1.109 + - 
5 0.983 0.972 + + 
6 1.008 1.014 - - 
7 1.025 1.028 - - 
8 1.028 1.022 - - 
9 1.023 1.002 - - 
10 0.991 0.971 + + 
11 1.02 1.017 - - 
12 0.955 0.987 + + 
13 1.075 1.004 - - 
14 1.012 1.012 - - 
15 1.004 1.021 - - 
16 0.988 0.971 + + 
17 0.991 0.988 + + 
18 1.017 0.997 - + 
19 1.028 1.027 - - 
20 1.007 1.062 - - 
21 1.015 1.014 - - 
22 1.009 1.039 - - 
23 0.898 0.94 + + 
24 0.984 0.994 + + 
25 0.999 0.959 + + 
 
 
